Overview

Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:
0

Participant gender:
All

Summary

This study aimed to investigate the impact of intensive cholesterol-lowering therapy (including evolocumab), drug treatment for high-risk plaques (Vulnerable plaques) with a high probability of developing acute coronary syndrome. The purpose of this study is to determine the effect of the change in the Lipid core burden index and compare the rate of cardiac events over 12 months following cholesterol therapy.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Korea University Anam Hospital

Treatments:

Evolocumab

Criteria

Inclusion Criteria:

1. Over 19 years old

2. Patients who agree to the study plan and clinical follow-up plan, voluntarily decide
to participate in this study, and consent in writing to the consent to use information

3. Patients who underwent NIRS-IVUS guided coronary stent surgery for acute coronary
syndrome

4. Patients who did not meet the LDL-Cholesterol level (<70mg/dL) even after receiving
the maximum dose of combined cholesterol therapy for 2 months

Exclusion Criteria:

1. Subjects with known hypersensitivity or contraindications to the following drugs or
substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin,
ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And
contrast agents (however, even a subject who is hypersensitive to contrast agents can
register if they can be controlled by steroids and pheniramine, except for known
anaphylaxis.)

2. Pregnant women, lactating women, or women of childbearing age who plan to become
pregnant during this study

3. Subjects who plan to have surgery to stop antiplatelet drugs within 12 months from
registration

4. Those whose surviving life is expected to be less than 1 year

5. Subjects who visited the hospital due to psychogenic shock and are predicted to have
low survival probability based on medical judgment

6. Subjects participating in a randomized study on cholesterol therapy